- Consultant Ophthalmic Surgeon
Mr Balaggan was appointed as a Consultant Ophthalmic Surgeon at New Cross Hospital in 2015 after completing the vast majority of his ophthalmic training at Moorfields Eye Hospital. He is currently Director of the Vitreo-retinal service, and Lead for Information Technology and Undergraduate Education at Wolverhampton Eye Infirmary.
- Complex Cataract
- Micro-incision Cataract
- Anterior Segment Reconstruction
- Medical Retina
Mr Balaggan performs routine and complex cataract surgery in addition to vitreoretinal surgery including the treatment of retinal detachments, epiretinal membranes, macula holes and diabetic complications.
As a vitreoretinal surgeon, Mr Balaggan is referred complex cataract cases from his colleagues, locally and regionally. This includes both complex cataracts as well as complications of other surgeons ‘ procedures. Only vitreoretinal surgeons can deal with all possible unexpected and expected intraoperative complications arising from cataract surgery.
Mr Balaggan obtained a PhD from University College London (ranked in the top five universities globally) developing state-of-the-art Gene Therapy for age-related macular degeneration as well as other retinal disorders. He has been awarded numerous prizes recognising his contribution to advancing frontiers in ophthalmology and for his teaching excellence. He is considered an expert in retinal medicine and surgery, and is often invited to lecture both nationally and internationally, teaching other retinal specialists.
With an outstanding track record in research and teaching, He spent four years full-time at University College London, under the guidance of internationally-awarded Professor Robin Ali, performing cutting-edge research developing novel retinal gene-based therapies for age-related macular degeneration and inherited retinal disorders.
Mr Balaggan was also a co-investigator in the world’s first gene therapy trial for an inherited retinopathy (New England Journal of Medicine 2008, 2015), and more recently a key investigator in the first randomised clinical evaluation of subconjunctival bevacizumab for new-onset corneal neovascularisation (British Journal of Ophthalmology, 2012). I co-designed and am the Principal Investigator in a new clinical trial based at Moorfields Eye Hospital, which will evaluate a novel radiotherapy device for the treatment of macular degeneration.